Forge Biologics, acquired by Ajinomoto Group in 2023 for $554-620 million, is a gene therapy CDMO specializing in high-purity adeno-associated virus (AAV) vector and plasmid manufacturing. The company operates a 200,000 sq ft Hearth facility in Columbus, Ohio with 20 cGMP suites and 20,000L bioreactor capacity, providing end-to-end services from preclinical process development through commercial manufacturing.
AAV vector manufacturing, plasmid production, gene therapy CDMO, process development, cGMP manufacturing
1 site worldwide
Involvement in 1 clinical trial
No certifications on file yet.
No reviews available yet.
No documents available.